Poolbeg Pharma (LON:POLB – Get Free Report) announced its earnings results on Monday. The company reported GBX (0.43) EPS for the quarter, Digital Look Earnings reports.
Poolbeg Pharma Stock Performance
Shares of LON POLB opened at GBX 3.71 on Tuesday. The firm has a market capitalization of £25.87 million, a price-to-earnings ratio of -319.83 and a beta of 2.11. The stock has a 50 day moving average price of GBX 3.35 and a 200 day moving average price of GBX 3.12. Poolbeg Pharma has a 52-week low of GBX 2.25 and a 52-week high of GBX 9.60.
Analyst Upgrades and Downgrades
Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a research report on Friday.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).
Featured Articles
- Five stocks we like better than Poolbeg Pharma
- How to Invest in Insurance Companies: A Guide
- Qualcomm Is on Its Biggest Uptrend in 2 Years—Can It Continue?
- Insider Trading – What You Need to Know
- Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
- How to Find Undervalued Stocks
- Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
